Legend Biotech Corporation (NASDAQ:LEGN) is among the many healthcare names vying for a breakthrough in cancer treatment. Last week, the New Jersey-based company had just that. On April 19th, a data ...
Investor's Business Daily on MSN
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
Arcellx stock reversed lower Monday despite positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti. Please watch the video at Investors.com - How To Buy Stocks: IBD's ...
New Jersey-based Legend Biotech announced its Q2 earnings on Monday, reporting $439m of revenues for its only commercial product, the cell therapy Carvykti. Carvykti leads CAR-T therapy sales with ...
CARVYKTI Q4 sales surge 66% to $555M, manufacturing scales up, and company targets enterprise profitability by 2026.
One stock that might be an intriguing choice for investors right now is Legend Biotech Corporation LEGN. This is because this security in the Medical - Biomedical and Genetics space is seeing solid ...
Legend Biotech (NASDAQ:LEGN) shares gained over 6% on Friday after an expert panel of the EU drug regulator, the European Medicines Agency (EMA), adopted a positive opinion for the label expansion of ...
Tuesday, H.C. Wainwright reaffirmed its Buy rating on shares of Legend Biotech Corp . (NASDAQ:LEGN) shares, maintaining a $73 ...
Shares of Legend Biotech Corp. LEGN gained 3.7% premarket on Thursday after the company said its multiple myeloma therapy Carvykti, a collaboration with Johnson & Johnson JNJ, generated $117 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results